Lessons from the withdrawal of rofecoxib - Patients would be safer if drug companies disclosed adverse events before licensing

被引：95

作者：

Dieppe, PA ^{[1
]}

Ebrahim, S

Martin, RM

Juni, P

机构：

[1] Univ Bristol, MRC Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England

[2] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England

[3] Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland

[4] Univ Bern, Dept Rheumatol, CH-3012 Bern, Switzerland

来源：

BRITISH MEDICAL JOURNAL | 2004年 / 329卷 / 7471期

关键词：

D O I：

10.1136/bmj.329.7471.867

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：867 / +

页数：3

共 14 条

[1] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[2] Selective COX-2 inhibitors, NSAIDs, aspirin, myocardial infarction [J].

Dalen, JE .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (10) :1091-1092

[3] Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs [J].

Dieppe, P ;

Bartlett, C ;

Davey, P ;

Doyal, L ;

Ebrahim, S .

BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7456) :31-34

[4] Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDs [J].

Jüni, P ;

Dieppe, P .

AGE AND AGEING, 2004, 33 (02) :100-104

[5] Myocardial infarction associated with selective COX-2 inhibitors:: Questions remain [J].

Jüni, P ;

Dieppe, P ;

Egger, M .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (22) :2639-2640

[6] Are selective COX 2 hihibitors superior to traditional non steroidal anti-inflammatory drugs?: Adequate analysis of the CLASS trial indicates that this may not be the case [J].

Jüni, P ;

Rutjes, AWS ;

Dieppe, PA .

BRITISH MEDICAL JOURNAL, 2002, 324 (7349) :1287-1288

[7] Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts [J].

Kargman, S ;

Charleson, S ;

Cartwright, M ;

Frank, J ;

Riendeau, D ;

Mancini, J ;

Evans, J ;

ONeill, G .

GASTROENTEROLOGY, 1996, 111 (02) :445-454

[8] Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study [J].

Layton, D ;

Riley, J ;

Wilton, LV ;

Shakir, SAW .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :166-174

[9]

Merck, 2004, MERCK ANN VOL WORLDW

[10] Risk of cardiovascular events associated with selective COX-2 inhibitors [J].

Mukherjee, D ;

Nissen, SE ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08) :954-959

← 1 2 →